We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Aspireo Reports Data in Further Phase Ib Study
News

Aspireo Reports Data in Further Phase Ib Study

Aspireo Reports Data in Further Phase Ib Study
News

Aspireo Reports Data in Further Phase Ib Study

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Aspireo Reports Data in Further Phase Ib Study"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Aspireo Pharmaceuticals Limited has reported final data from a further phase Ib study in healthy volunteers.

In this single-dose, randomized, 5-way cross-over study, healthy volunteers were treated with the highest approved dose of octreotide, three different doses of Somatoprim (DG3173) and placebo control.

The main purpose of the study was to investigate the effects of each treatment on the control of plasma glucose as well as the secretion of insulin and glucagon following a standard meal.

The final data demonstrate that octreotide significantly inhibits the secretion of insulin and glucagon in humans and shows a significant and sustained increase of plasma glucose levels.
In contrast, DG3173 has much less of an effect on insulin and glucagon release compared to octreotide, as well as the normalization of glucose control. This improved profile was observed even at high doses of DG3173.

Carsten Dehning, CEO of Aspireo Pharmaceuticals said: ”This study clearly demonstrates the superiority in the side effect profile of DG3173 over octreotide. These results confirm the findings from pre-clinical studies and support the unique profile of this promising investigational drug with respect to glycaemic control.”

Advertisement